Thu, Jan 29, 2015, 3:25 AM EST - U.S. Markets open in 6 hrs 5 mins


% | $
Quotes you view appear here for quick access.

Hologic Inc. Message Board

  • comsensea comsensea May 7, 2013 10:27 AM Flag

    Good numbers, Good products, Good furture (with Novartis)

    Hologic Inc. (HOLX) reported adjusted earnings per share of 35 cents in the second quarter of fiscal 2013, higher than the year-ago earnings of 33 cents as well as the company’s expectations of 33−34 cents for the reported quarter. The result also beat the Zacks Consensus Estimate by a penny.

    On a reported basis, net loss in the second quarter was $51.1 million or 19 cents per share, worse than the net loss of $40.3 million or 15 cents per share in the prior-year quarter.

    Revenues were $612.7 million in the quarter, up 30% year over year. Despite solid growth, the top line was significantly below the Zacks Consensus Estimate of $644 million and company’s guidance range of $635−$640 million. Revenues exclude the $6.4 million of contingent revenue received under a collaboration agreement of Gen-Probe with Novartis. Hologic completed the acquisition of Gen-Probe on Aug 1, 2012. Revenue growth was led by inclusion of Gen-Probe revenues, higher sales of MyoSure and tomosynthesis systems and wider installed base of digital mammography systems.

29.610.00(0.00%)Jan 28 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST
McDonald's Corp.
NYSEWed, Jan 28, 2015 4:00 PM EST
Exelixis, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST